Related Experiment Video
Updated: Jul 20, 2026

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
Published on: December 13, 2017
Oxcarbazepine use in essential tremor
Vidya Raj1, Jacqueline S Landess, Peter R Martin
1Vanderbilt University, Vanderbilt Psychiatric Hospital, Nashville, TN 37232-8650, USA.
Oxcarbazepine shows promise for treating essential tremor, offering a potential alternative to propranolol. This case report details significant symptom improvement, suggesting further research is warranted for this neurological disorder.
Area of Science:
- Neurology
- Pharmacology
Background:
- Essential tremor (ET) is a common neurological disorder.
- Current first-line treatments like propranolol have limitations, including variable pharmacokinetics and suboptimal response in some patients.
- Primidone, another option, carries abuse potential.
Observation:
- A patient with essential tremor inadequately managed by propranolol experienced significant tremor reduction with oxcarbazepine.
- The patient also had a history of substance abuse and neuropathic pain.
- Oxcarbazepine was initiated for neuropathic pain, leading to unexpected improvement in tremor symptoms.
Findings:
- Oxcarbazepine treatment resulted in a clinically significant reduction in essential tremor symptoms.
- The patient reported decreased pain scores concurrently with tremor improvement.
- This represents the first reported case of oxcarbazepine effectively treating essential tremor.
Implications:
- Oxcarbazepine may offer a novel therapeutic option for essential tremor.
- Advantages include a favorable tolerability profile and lack of abuse potential compared to existing treatments.
- Further clinical trials are necessary to validate these preliminary findings and explore oxcarbazepine's efficacy in a broader patient population.
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Glutamate Antagonists

